F Lalloo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10991766/publications.pdf

Version: 2024-02-01

64 papers	7,358 citations	125106 35 h-index	124990 64 g-index
64 all docs	64 docs citations	64 times ranked	8002 citing authors

#	Article	IF	Citations
1	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, 75, 69-76.	0.5	9
2	Are women with pathogenic variants in PMS2 and MSH6 really at high lifetime risk of breast cancer?. Genetics in Medicine, 2019, 21, 1878-1879.	1.1	6
3	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 167, 779-785.	1.1	9
4	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. Familial Cancer, 2017, 16, 173-179.	0.9	2
5	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment, 2016, 155, 597-601.	1.1	29
6	Colonoscopy screening compliance and outcomes in patients with Lynch syndrome. Colorectal Disease, 2015, 17, 38-46.	0.7	63
7	TheBRCA2polymorphic stop codon: stuff or nonsense?. Journal of Medical Genetics, 2015, 52, 642-645.	1.5	12
8	Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey. Clinical Genetics, 2015, 87, 517-524.	1.0	18
9	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer, 2015, 14, 531-538.	0.9	45
10	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Familial Cancer, 2014, 13, 189-196.	0.9	22
11	TumourMLH1promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). Journal of Medical Genetics, 2014, 51, 789-796.	1.5	69
12	Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. British Journal of Surgery, 2013, 100, 1719-1731.	0.1	104
13	Is multiple <scp>SNP</scp> testing in <scp>BRCA2</scp> and <scp>BRCA1</scp> female carriers ready for use in clinical practice? Results from a large Genetic Centre in the <scp>UK</scp>. Clinical Genetics, 2013, 84, 37-42.	1.0	12
14	The spectrum of urological malignancy in Lynch syndrome. Familial Cancer, 2013, 12, 57-63.	0.9	50
15	Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer, 2012, 106, 775-779.	2.9	22
16	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
17	Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer, 2012, 11, 235-242.	0.9	252
18	Genotypeâ€“phenotype correlation in colorectal polyposis. Clinical Genetics, 2012, 81, 521-531.	1.0	41

#	Article	IF	Citations
19	Familial Breast Cancer. Clinical Genetics, 2012, 82, 105-114.	1.0	147
20	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. Journal of Medical Genetics, 2011, 48, 520-522.	1.5	69
21	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	2.9	7
22	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer, 2011, 105, 22-27.	2.9	60
23	RASSF1A polymorphism in familial breast cancer. Familial Cancer, 2010, 9, 263-265.	0.9	19
24	Breast cancer susceptibility variants alter risk in familial ovarian cancer. Familial Cancer, 2010, 9, 503-506.	0.9	4
25	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. British Journal of Cancer, 2010, 102, 1091-1098.	2.9	42
26	Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics, 2010, 47, 710-711.	1.5	98
27	The impact of screening and genetic registration on mortality and colorectal cancer incidence in familial adenomatous polyposis. Gut, 2010, 59, 1378-1382.	6.1	53
28	BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries. Journal of Medical Genetics, 2010, 47, 561-566.	1.5	7
29	Breast cancer susceptibility variants alter risks in familial disease. Journal of Medical Genetics, 2010, 47, 126-131.	1.5	35
30	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2318-2324.	1.1	132
31	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2009, 46, 811-817.	1.5	80
32	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
33	Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 2009, 75, 141-149.	1.0	280
34	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	1.5	80
35	Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Journal of Medical Genetics, 2009, 46, 593-597.	1.5	116
36	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461

#	Article	IF	Citations
37	Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clinical Genetics, 2008, 73, 338-345.	1.0	38
38	Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clinical Genetics, 2008, 74, 233-242.	1.0	85
39	Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	1.1	15
40	Desmoid tumours in patients with familial adenomatous polyposis and desmoid region adenomatous polyposis coli mutations. British Journal of Surgery, 2007, 94, 1009-1013.	0.1	53
41	Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics, 2006, 44, 10-15.	1.5	102
42	Non-random transmission of mutant alleles to female offspring in BRCA carriers. Journal of Medical Genetics, 2005, 42, e6-e6.	1.5	5
43	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
44	Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics, 2005, 42, e39-e39.	1.5	74
45	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology, 2005, 31, 1112-1118.	0.5	41
46	Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. Journal of Medical Genetics, 2004, 41, 21e-21.	1.5	17
47	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. Journal of Medical Genetics, 2004, 41, 474-480.	1.5	232
48	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
49	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. Journal of Medical Genetics, 2003, 40, 807-814.	1.5	261
50	Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families. Journal of Medical Genetics, 2003, 40, 107e-107.	1.5	13
51	Re: Risk-Reduction Mastectomy: Clinical Issues and Research Needs. Journal of the National Cancer Institute, 2002, 94, 307-307.	3.0	4
52	Risk assessment and management of high risk familial breast cancer. Journal of Medical Genetics, 2002, 39, 865-871.	1.5	53
53	Uptake of screening and prevention in women at very high risk of breast cancer. Lancet, The, 2001, 358, 889-890.	6.3	56
54	Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Familial Cancer, 2001, 1, 65-72.	0.9	45

#	Article	IF	Citations
55	Clinical follow-up after bilateral risk reducing (?prophylactic?) mastectomy: mental health and body image outcomes. Psycho-Oncology, 2000, 9, 462-472.	1.0	121
56	Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. Journal of Medical Genetics, 2000, 37, 792-794.	1.5	15
57	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. European Journal of Surgical Oncology, 2000, 26, 711-713.	0.5	35
58	Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer. Disease Markers, 1999, 15, 207-211.	0.6	55
59	Utilisation of Prophylactic Mastectomy in 10 European Centres. Disease Markers, 1999, 15, 148-151.	0.6	29
60	Efficacy of Early Diagnosis and Treatment in Women with a Family History of Breast Cancer. Disease Markers, 1999, 15, 179-186.	0.6	35
61	Management of Hereditary Breast Cancer. Disease Markers, 1999, 15, 187-189.	0.6	8
62	Screening by mammography, women with a family history of breast cancer. European Journal of Cancer, 1998, 34, 937-940.	1.3	82
63	Haplotype and Phenotype Analysis of Nine Recurrent BRCA2 Mutations in 111 Families: Results of an International Study. American Journal of Human Genetics, 1998, 62, 1381-1388.	2.6	150
64	An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.. Journal of Medical Genetics, 1998, 35, 10-12.	1.5	11